Decrease in Chitinase 3-Like Protein 1 Levels Reflects Improvement in Liver Fibrosis after HCV Eradication
Table 2
Dynamic changes of serum CHI3L1 levels in SOF-based regimens treated patients and PR-experienced patients.
T0
T1
T2
T3
P01
P12
P23
P02
P03
DAA-all
123.79 (118.55)
118.20 (103.68)
98.46 (96.49)
91.19 (98.63)
0.001
0.474
0.05
0.001
<0.001
DAA-ascender (11/46)
107.13 (81.24)
149.85 (61.72)
97.90 (95.31)
128.97 (143.23)
0.003
0.075
0.678
DAA-decliner (35/46)
135.79 (150.17)
104.79 (76.053)
99.03 (97.936)
90.69 (81.94)
<0.001
0.682
0.029
PR-all
89.15 (110.59)
81.01 (112.13)
69.98 (51.44)
85.40 (61.03)
0.555
0.003
0.925
0.016
0.036
PR-ascender (14/34)
84.06 (107.79)
115.50 (210.724)
88.48 (94.6171)
93.18 (80.57)
0.001
0.004
0.272
PR-decliner (20/34)
135.86 (98.9372)
68.56 (64.06)
63.05 (41.88)
83.90 (52.07)
<0.001
0.263
0.247
Median and interquartile ranges in brackets are shown. T0: the baseline; T1: the end of treatment; T2: 24 weeks after treatments; T3: 48 weeks after treatments. P01: values comparing T0 to T1; P02: values comparing T0 to T2; P12: values comparing T1 to T2; P23: values comparing T2 to T3.
